Certara's 81% Sprint Into a 2–3% Guide

Software finally grew double digits, services still shrank — and the AI partnership and multiyear path that powered the last two calls quietly went missing.

CERT · Earnings Call · 2026-11-05

A rally looking for a number it didn't get

Certara's tape has done something unambiguous over the last 90 trading days: one unbroken leg, up 81%. The full history is far grimmer — down 68% since the December 2020 debut, 73% below the November 2021 peak of $45.21 — so what the market bought was a turnaround option, not a turnaround. Then management delivered the number underneath it. Full-year revenue growth was narrowed to 2%–3%, with services guided "at or below the low end of that range." “We are narrowing our 2026 full-year revenue growth range to 2%-3%.” — Faiz Mohammed, Interim Chief Financial Officer · 2026-11-05 An 81% move and a low-single-digit revenue outlook are not usually found in the same paragraph. That gap is the story.

The software inflection is real; the services excuse is three quarters old

For the first time in two years the core engine turned: software revenue rose 11% to $48.8M, software bookings $46.9M (+15%), and software now exceeds half the company. Total bookings grew just 4%, which tells you everything about the other half. Services fell 2% to $46.1M with a trailing book-to-bill of 1.15 — sequentially better by 3.5%, but still contracting year over year. This is the software growth story management has been promising since Jon Resnick arrived in January.

What is new is how the CEO now frames the split. Asked to separate demand from execution, he credited the market first: “I think, like others, the end market looks strong. I think that's seen across the industry... The execution certainly is part of the story.” — Jon Resnick, Chief Executive Officer · 2026-11-05 That is a meaningful shift. On the August call he was adamant the opposite way — “I think we're not dependent on biotech funding or market health at this point. This is an execution component.” — Jon Resnick, Chief Executive Officer · 2026-08-04 When the software number is good you credit the end market; when services miss, you blame your own go-to-market. That asymmetry is worth flagging.

And the services diagnosis has not changed in nine months — “I don't think there's any end market distinction... our service performance is really a result of changes we made from a go-to-market standpoint.” — Jon Resnick, Chief Executive Officer · 2026-11-05 Same words, same specialist-led sales model, same "second quarter of making those changes" language as August. The promised revenue translation keeps being one or two quarters out.

What management stopped saying

The instructive part of this call is the silence. In the June quarter the NVIDIA partnership and the "next-generation AI platform" were the marquee items — a standing theme across both the February and August Q&As. This quarter NVIDIA does not appear once. AI has been reframed and de-risked: an agentic component that plugs into customer workflows, an MCP-enabled data layer, and a contribution timeline that has slipped to "2027." That is the market-wide Agentic AI language every software reporter is now using — Certara simply joined it late and without a ship date.

Likewise gone: stranded costs, which ranked near the top of the keyword set last quarter as the justification for the margin reset. The cost-savings tally also went deliberately vague. After flagging "$10 million" in February and "exceeding $12 million or $13 million" in August, this quarter: “We didn't give specific numbers this quarter... I think that has continued to grow.” — Jon Resnick, Chief Executive Officer · 2026-11-05 Margin, meanwhile, did the work — 31.8% adjusted EBITDA, up more than 370bps sequentially, exactly as the May/June reduction-in-force was designed to deliver.

We're not going to provide a multiyear path today... if not at the next set of calls early into Q3, we'll be providing that multiyear guidance and a clear direction and path for you.
Jon Resnick, Chief Executive Officer · 2026-02-26

That was February. August came and went. November: “We're going to hold off in terms of providing guidance until later in the year at this point. I got no incremental updates to provide.” — Jon Resnick, Chief Executive Officer · 2026-11-05 A company that has finished its divestiture, reorganized into two segments, hired a new CCO and now a new CPO, and watched its stock double is exactly the company that should have a 2027 frame to offer. It declined.

The one genuine tailwind — and what the numbers say

Regulatory is where Certara's rhetoric is best supported. The FDA awarded contracts at CDER (DataFit) and CBER (CASA-CV), extended Pinnacle 21's run since 2011, and engaged Simcyp on a three-year dermal biosimulation contract; ICH M15 is now effective, TrialBlazer is in execution, and ARPA-H's SURPASS program funds simulation-driven trials. Resnick's diffusion curve framing — new approach methodologies sitting "between phase II and phase III" — is honest about timing rather than promotional about it.

Same honesty is warranted about the cloud shift. Nearly 10% of accounts have moved to Phoenix Cloud, ahead of plan, and management concedes it mutes near-term revenue: “There is going to be, there is a little bit of a revenue headwind that exists with it, as you kind of start to do some of those conversions.” — Jon Resnick, Chief Executive Officer · 2026-11-05 That is a real, if modest, drag embedded in the 2%–3% guide.

The fundamentals are why the multiple had compressed so violently in the first place. Price to revenue sits at 2.4x, down roughly 88% from the 2020 peak — the stock was priced for a broken model. The GAAP picture remains ugly: a net loss of $55M in the June quarter, a -59% net margin, and free cash flow ex-SBC of $9M in Q2. Reported Q3 cash of $214.9M against a $293M term loan still nets to a modest debt position — not a problem, but not the "fortress" some turnaround narratives imply.

One last market contrast: the cluster the tape spent 90 days punishing was AI data centers, down roughly 30%. Certara, up 81%, is the inverse trade — money rotating out of capex-heavy AI infrastructure into cheap, idiosyncratic, self-help healthcare software. That is a real bid. It is not yet an earnings bid. Until services stops shrinking and the 2027 path arrives, the stock is discounting a recovery the P&L has only half delivered.